Ascendis Pharma A/S
ASND
158 hedge funds and large institutions have $5.45B invested in Ascendis Pharma A/S in 2023 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 60 increasing their positions, 55 reducing their positions, and 33 closing their positions.
63% more call options, than puts
Call options by funds: $43.5M | Put options by funds: $26.7M
9% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 55
0.06% more ownership
Funds ownership: 106.75% → 106.81% (+0.06%)
4% less funds holding
Funds holding: 164 → 158 (-6)
17% less capital invested
Capital invested by funds: $6.54B → $5.45B (-$1.09B)
18% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 33
38% less funds holding in top 10
Funds holding in top 10: 13 → 8 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$371M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$44.3M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
+$42.3M |
| 4 |
FAM
Fred Alger Management
New York
|
+$30.5M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$30.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$187M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$114M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$67.1M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$54.2M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
-$37.6M |
ASND Hedge Fund Activity: Q2 2023 in Review
158 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q2 2023, worth a combined $5.45B — down 17% from $6.54B a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of ASND and 27 opened new positions — a net loss of 6 holders — while 55 trimmed existing stakes and 60 added.
The largest buyer was RA Capital Management, adding an estimated $371M. The largest seller was Goldman Sachs, cutting an estimated $187M.
- 158 institutional investors held Ascendis Pharma A/S (ASND) as of Q2 2023, down from 164 in Q1 2023.
- Funds reported $5.45B of Ascendis Pharma A/S stock for Q2 2023, down 17% quarter-over-quarter.
- 27 funds opened new Ascendis Pharma A/S positions in Q2 2023 and 33 closed out, a net change of -6 holders.
- The largest Ascendis Pharma A/S buyer in Q2 2023 was RA Capital Management, an estimated $371M added.
- The largest Ascendis Pharma A/S seller in Q2 2023 was Goldman Sachs, an estimated $187M sold.
Based on aggregated 13F filings for Q2 2023.